- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT00260208
Liver Fibrosis in Patients Transplanted for Hepatitis C Receiving Either Cyclosporine Microemulsion or Tacrolimus
A Multicenter, Randomized, Open-label Study to Compare the Development of Liver Fibrosis at 12 Months After Transplantation for Hepatitis C Cirrhosis in Patients Receiving Either Cyclosporine Microemulsion or Tacrolimus
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 4
Kontakte und Standorte
Studienorte
-
-
-
Zurich, Schweiz, 8091
- Novartis Investigational site
-
-
-
-
New Jersey
-
East Hanover, New Jersey, Vereinigte Staaten
- Novartis Investigative Site
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion criteria
- Reason for transplant is end-stage liver disease due to hepatitis C cirrhosis
- Patients receiving a first liver transplant from a deceased or living donor
- Patients in whom biopsies will be possible
Exclusion criteria
- Recipients of a liver from an hepatitis C virus positive (HCV+), human immunodeficiency virus positive (HIV+) or hepatitis B virus positive (HBV+) donor
- Patients with any severe coexisting disease or suffering any unstable medical condition or co-infected with HBV or HIV
- Patients with co-existing alcoholic disease who have not been abstinent for at least 6 months
- Transplanted for liver cancer exceeding a pre-defined size
- Pregnant or nursing women
Other protocol-defined inclusion/exclusion criteria may apply
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Verhütung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Aktiver Komparator: Cyclosporin A
The first administration of Cyclosporin A (CsA) was within the first 24 hours post-transplantation at an initial dose of 10-15mg/kg/day either orally, via a nasogastric (NG) tube or intravenously (i.v). Twice daily (b.i.d.) administration was maintained throughout the study period. During the study, the dose of CsA was adjusted, as necessary, to achieve and maintain the C2 or C0 blood CsA concentration within the target ranges. Before enrolling the first patient, each center chose the adjunct immunosuppressive (IS) regimen between:
The regimen selected by the center was to be given to all patients enrolled in the trial from this center. |
Initial dose of 10-15mg/kg/day either orally, via a nasogastric (NG) tube or intravenously (i.v.) within the first 24 hours post-transplantation.
Andere Namen:
|
Aktiver Komparator: Tacrolimus
Tacrolimus was administered within the first 24 hours post-transplantation at an initial dose of 0.1-0.15 mg/kg/day in 2 divided doses (twice daily at 12-hour interval) either orally or via a nasogastric (NG) tube or intravenously (i.v). Twice daily (b.i.d.) administration was maintained throughout study period. Throughout the study, the dose of tacrolimus was adjusted as necessary to achieve and maintain C0 tacrolimus concentrations within target ranges. Before enrolling the first patient, each center chose adjunct immunosuppressive (IS) regimen between:
The regimen selected by center was to be given to all patients enrolled in trial from this center. |
Tacrolimus was administered within the first 24 hours post-transplantation at an initial dose of 0.1-0.15
mg/kg/day in 2 divided doses either orally or via a nasogastric (NG) tube or intravenously (i.v).
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Number of Participants With Fibrosis Score 2 or Above [Ishak-Knodell Fibrosis Score (FS) ≥ 2] Within 1 Year Post-transplant
Zeitfenster: 1 year post-transplant
|
Assessment of hepatic fibrosis was performed with liver biopsies at Day 1, Month 6, 12 and 24, read centrally by two independent pathologists blinded to treatment arm and time of biopsy.
Ishak-Knodell score was used to stage liver disease; 0= None; 1= Portal fibrosis (some); 2= Portal fibrosis (most); 3= Bridging fibrosis (few); 4= Bridging fibrosis (many); 5 = Incomplete cirrhosis; 6 = Cirrhosis.
Higher score indicates greater fibrosis.
Logistic regression on the presence of IK>=2 was applied based on central biopsy readings only.
|
1 year post-transplant
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Number of Participants With Combined Endpoint of Death or Graft Loss or Fibrosis Score (FS) ≥ 2
Zeitfenster: 1 year post-transplant
|
The number of participants with combined end point of death or graft loss or presented with a Ishak-Knodell fibrosis score (FS) ≥2 was calculated.
Graft loss was considered to have occurred when allograft was presumed to be lost if a patient had liver retransplant or died.
Assessment of hepatic fibrosis was performed with liver biopsies read centrally.
Ishak-Knodell FS was used to stage liver disease; 0=none; 1=portal fibrosis (some); 2=portal fibrosis (most); 3=bridging fibrosis (few); 4=bridging fibrosis (many); 5=Incomplete cirrhosis; 6=cirrhosis.
Higher score indicates greater fibrosis.
|
1 year post-transplant
|
Number of Participants With Fibrosing Cholestatic Hepatitis
Zeitfenster: 1 year post-transplantation
|
Fibrosing cholestatic hepatitis (FCH) is characterized by progressive jaundice with a rapid decline in liver function leading to liver failure, most often associated with markedly elevated viral levels detected in the bloodstream (e.g. more than 20 times pre-liver transplantation levels) and in the liver tissue as well.
The presence of FCH was reported based on the diagnosis given by the investigator.
|
1 year post-transplantation
|
Number of Participants With Death, Graft Loss, Death or Graft Loss, Graft Loss With Re-transplantation
Zeitfenster: 1 year post-transplant
|
Graft loss was considered to have occurred when allograft was presumed to be lost if a patient had a liver re-transplant or died.
|
1 year post-transplant
|
Number of Participants With Treated Acute Rejection, Biopsy Proven Acute Rejection (BPAR), and Sub-clinical Rejection
Zeitfenster: 1 year post-transplant
|
Treated acute rejection is defined as an acute rejection, clinically suspected, whether biopsy-proven or not, which has been treated and confirmed by the investigator according to the response to therapy.
BPAR was defined as a treated acute rejection confirmed by biopsy.
The local pathologist graded biopsies according to the Banff (1997) criteria.
A sub-clinical rejection was defined as a rejection identified by center driven biopsy, i.e. a biopsy performed routinely at some pre-defined time points after transplantation as per center practice in the absence of any clinical signs of rejection.
|
1 year post-transplant
|
Number of Participants With Combined Endpoint of Death or Graft Loss or Biopsy Proven Acute Rejection (BPAR)
Zeitfenster: 1 year post-transplant
|
BPAR was defined as a treated acute rejection confirmed by biopsy.
The local pathologist graded biopsies according to the Banff (1997) criteria.
Graft loss was considered to have occurred when allograft was presumed to be lost if a patient had a liver re-transplant or died.
|
1 year post-transplant
|
Number of Participants With Death or Re-transplantation Due to Recurrence of Hepatitis C Cirrhosis
Zeitfenster: 1 year post-transplant
|
Cirrhosis was resulted due to the recurrence of the hepatitis C virus infection in the transplanted liver.
|
1 year post-transplant
|
Number of Participants With Fibrosis Score 2 or Above [Ishak-Knodell Fibrosis Score (FS) ≥ 2] Within 1 Year Post-transplant (Intent to Treat Population)
Zeitfenster: 1 year post-transplant
|
Assessment of hepatic fibrosis was performed with liver biopsies at Day 1, Month 6, 12 and 24, read centrally by two independent pathologists blinded to treatment arm and time of biopsy.
Ishak-Knodell score was used to stage liver disease; 0= None; 1= Portal fibrosis (some); 2= Portal fibrosis (most); 3= Bridging fibrosis (few); 4= Bridging fibrosis (many); 5 = Incomplete cirrhosis; 6 = Cirrhosis.
Higher score indicates greater fibrosis.
|
1 year post-transplant
|
Mean Value of Liver Function Tests at 1 Year Post-transplantation
Zeitfenster: 1 year post-transplant
|
The mean value (in Units per liter, IU/L) of following tests were calculated at 1 year post-transplant:
|
1 year post-transplant
|
Log-transformed Hepatitis C Virus Ribonucleic Acid (HCV RNA) Values up to 1 Year Post Transplant
Zeitfenster: Pre-transplant (Day 1), Day , Day 8, Day 29, Month 6 and 12 post- transplant
|
HCV RNA was measured (IU/µL)centrally pre-transplant (Day 1) and at 48 hours (Day 3), Day 8 and 29, Month 6 and 12 post-transplant and concomitantly to any additional biopsies performed.
|
Pre-transplant (Day 1), Day , Day 8, Day 29, Month 6 and 12 post- transplant
|
Percentage of Participants With an Increase of at Least 1 Stage in Fibrosis
Zeitfenster: Between 1 and 2 years
|
Assessment of hepatic fibrosis was performed with liver biopsies at Day 1, Month 6, 12 and 24, read centrally by two independent pathologists blinded to treatment arm and time of biopsy.
Ishak-Knodell score was used to stage liver disease; 0= None; 1= Portal fibrosis (some); 2= Portal fibrosis (most); 3= Bridging fibrosis (few); 4= Bridging fibrosis (many); 5 = Incomplete cirrhosis; 6 = Cirrhosis.
Higher score indicates greater fibrosis.
An increase of at least 1 stage demonstrated a worsening of the disease, i.e. the transition from one score to the next higher one.
|
Between 1 and 2 years
|
Mean Fibrosis Score
Zeitfenster: At 1and 2 years and its evolution over time
|
Assessment of hepatic fibrosis was performed with liver biopsies at Day 1, Month 6, 12 and 24, read centrally by two independent pathologists blinded to treatment arm and time of biopsy.
Ishak-Knodell score was used to stage liver disease; 0= None; 1= Portal fibrosis (some); 2= Portal fibrosis (most); 3= Bridging fibrosis (few); 4= Bridging fibrosis (many); 5 = Incomplete cirrhosis; 6 = Cirrhosis.
Higher score indicates greater fibrosis.
The mean score was equivalent to mean of IK at 1 and 2 years (evolution over time).
|
At 1and 2 years and its evolution over time
|
Mitarbeiter und Ermittler
Sponsor
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Erkrankungen des Verdauungssystems
- Pathologische Prozesse
- RNA-Virusinfektionen
- Viruserkrankungen
- Infektionen
- Durch Blut übertragene Infektionen
- Übertragbare Krankheiten
- Leberkrankheiten
- Flaviviridae-Infektionen
- Hepatitis, viral, menschlich
- Enterovirus-Infektionen
- Picornaviridae-Infektionen
- Fibrose
- Hepatitis
- Hepatitis A
- Hepatitis C
- Leberzirrhose
- Physiologische Wirkungen von Arzneimitteln
- Molekulare Mechanismen der pharmakologischen Wirkung
- Antiinfektiva
- Enzym-Inhibitoren
- Antirheumatika
- Immunsuppressive Mittel
- Immunologische Faktoren
- Dermatologische Wirkstoffe
- Antimykotika
- Calcineurin-Inhibitoren
- Tacrolimus
- Cyclosporin
- Cyclosporine
Andere Studien-ID-Nummern
- COLO400A2426
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Hepatitis C
-
Tripep ABInovio PharmaceuticalsUnbekanntChronische Hepatitis-C-VirusinfektionSchweden
-
Hadassah Medical OrganizationXTL BiopharmaceuticalsZurückgezogenChronische Hepatitis-C-VirusinfektionIsrael
-
Hadassah Medical OrganizationUnbekanntChronische Hepatitis-C-VirusinfektionIsrael
-
Trek Therapeutics, PBCAbgeschlossenChronische Hepatitis C | Hepatitis-C-Genotyp 1 | Hepatitis C (HCV) | Hepatitis-C-VirusinfektionVereinigte Staaten, Neuseeland
-
Trek Therapeutics, PBCAbgeschlossenChronische Hepatitis C | Hepatitis C (HCV) | Hepatitis-C-Genotyp 4 | Hepatitis-C-VirusinfektionVereinigte Staaten
-
AbbVieAbgeschlossenChronische Hepatitis C | Hepatitis C (HCV) | Hepatitis-C-Genotyp 1a
-
AbbVie (prior sponsor, Abbott)AbgeschlossenChronische Hepatitis C | Hepatitis-C-Genotyp 1 | Hepatitis C (HCV)Vereinigte Staaten, Australien, Kanada, Frankreich, Deutschland, Neuseeland, Puerto Rico, Spanien, Vereinigtes Königreich
-
AbbVieAbgeschlossenHepatitis-C-Virus | Chronisches Hepatitis-C-Virus
-
Beni-Suef UniversityAbgeschlossenChronische Hepatitis-C-VirusinfektionÄgypten
-
Humanity and Health Research CentreBeijing 302 HospitalAbgeschlossenChronische Hepatitis-C-InfektionChina
Klinische Studien zur Cyclosporine A
-
AllerganAbgeschlossenSyndrome des trockenen AugesVereinigte Staaten
-
Institute of Hematology & Blood Diseases HospitalUnbekanntStörungen beim Wasserlassen | Thrombose | Proteinurie | Anämie, hämolytisch | Hämoglobinurie, paroxysmal | Hämoglobinurie | Paroxysmale nächtliche Hämoglobinurie | Knochenmarkversagen | Aplastische Anämie,China
-
Institute of Hematology & Blood Diseases HospitalUnbekanntStörungen beim Wasserlassen | Thrombose | Proteinurie | Anämie, hämolytisch | Hämoglobinurie, paroxysmal | Hämoglobinurie | Paroxysmale nächtliche Hämoglobinurie | Knochenmarkversagen | Aplastische Anämie,China
-
Shandong UniversityNational Natural Science Foundation of ChinaUnbekannt
-
Zambon SpAAnmeldung auf EinladungBronchiolitis obliterans | Bronchiolitis obliterans-Syndrom | Obliterative BronchiolitisFrankreich, Vereinigte Staaten, Spanien, Israel, Belgien, Dänemark, Deutschland, Vereinigtes Königreich, Österreich
-
Safaa AA KhaledAssiut UniversityAbgeschlossenAplastische AnämieÄgypten
-
Bing HanAbgeschlossenPure Red Cell Aplasia, erworbenChina
-
Hospices Civils de LyonAbgeschlossenST-Hebung Akuter MyokardinfarktFrankreich, Spanien, Belgien
-
Mahidol UniversityAbgeschlossenStevens-Johnson-SyndromThailand
-
LEO PharmaZurückgezogenAtopische DermatitisNiederlande